Daily Sepsis Research Analysis
Analyzed 47 papers and selected 3 impactful papers.
Summary
Three mechanistic studies advance host-directed therapy for sepsis-related organ dysfunction. A biomimetic nanovesicle targeting the BMAL1/PFKFB3 axis in alveolar macrophages mitigates sepsis-associated ARDS; endothelial autophagy is identified as a driver of blood–brain barrier failure and lethality; and complement C3aR1 orchestrates macrophage–neutrophil crosstalk to induce cardiotoxic necroptosis in sepsis-induced myocardial injury.
Research Themes
- Host-directed therapies in sepsis
- Immunometabolism and circadian regulation
- Organ-specific mechanisms in SA-ARDS, BBB injury, and myocardial dysfunction
Selected Articles
1. Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.
The authors identify BMAL1 in alveolar macrophages as a metabolic brake on PFKFB3-driven glycolysis and M1 polarization during SA-ARDS. A biomimetic, inhaled nanoplatform (RM@TNT) delivers a BMAL1 agonist to alveolar macrophages, suppresses glycolysis and inflammation, mitigates lung injury and edema, and improves survival in mice.
Impact: This study couples a clearly defined immunometabolic mechanism (BMAL1/PFKFB3) with a precision delivery platform, offering a plausible, organ-targeted therapy for SA-ARDS where options are scarce.
Clinical Implications: While preclinical, targeting AM glycolysis via BMAL1 activation and inhaled delivery could enable host-directed therapy to dampen lung inflammation in sepsis and complement supportive care for acute respiratory failure.
Key Findings
- BMAL1 represses PFKFB3 transcription in alveolar macrophages to inhibit glycolysis and M1 polarization.
- An inhalable biomimetic nanoplatform (RM@TNT) targets alveolar macrophages using AM-membrane vesicles and ROS-responsive liposomes.
- RM@TNT delivery of a BMAL1 agonist reduces lung inflammation, injury, and edema and improves survival in SA-ARDS mice.
Methodological Strengths
- Mechanistic dissection linking BMAL1 to PFKFB3-mediated glycolysis and macrophage polarization.
- Integrated nanotechnology with organ-targeted delivery and in vivo efficacy with survival endpoints.
Limitations
- Findings are limited to murine SA-ARDS models; human validation is absent.
- Safety, biodistribution, and scalability of RM@TNT have not been assessed in large animals.
Future Directions: Validate BMAL1/PFKFB3 signatures in human SA-ARDS, assess RM@TNT safety/pharmacology in large animals, and design early-phase trials after dose-finding and manufacturability studies.
Sepsis-associated acute respiratory distress syndrome (SA-ARDS) is a life-threatening complication characterized by excessive pulmonary inflammation and pulmonary edema, lacking effective treatments. This study identifies the transcription factor BMAL1 in alveolar macrophages (AMs) as a key therapeutic target. Mechanistically, BMAL1 represses the expression of the glycolytic enzyme PFKFB3 by binding to the Pfkfb3 promoter, thereby inhibiting glycolysis, M1 polarization of AMs, and the generation of pro-inflammatory cytokines and reactive oxygen species (ROS). Based on this regulatory mechanism, a biomimetic nanoplatform, RM@TNT, is engineered for precise SA-ARDS therapy. Fabricated by hybridizing AM membrane-derived nanovesicles with ROS-responsive liposomes, the nanoplatform encapsulates tetrahedral DNA nanostructures (TNT) preloaded with nobiletin (Nob, a BMAL1 agonist) and Tuftsin (an AM-targeting peptide). Following inhalation, the AM membrane tropism of RM@TNT ensures prolonged pulmonary retention, prompting targeted TNT release within the ROS-rich pathological microenvironment. Tuftsin then precisely delivers TNT to AMs, where Nob is intracellularly released to activate BMAL1. This activation upregulates the BMAL1/PFKFB3 axis, suppressing AM glycolysis, inflammation, and oxidative stress. Treatment with RM@TNT resulted in significantly attenuated lung inflammation, injury, and edema, along with markedly improved survival in SA-ARDS mice. Collectively, this multimodal, targeted metabolic reprogramming approach is a highly promising therapeutic strategy for SA-ARDS.
2. Enhanced autophagy drives endothelial tight junction loss, BBB disruption, and behavioral deficits during inflammation.
Quantitative proteomics and functional assays show that heightened endothelial autophagy is a proximal driver of BBB leak during sepsis-like inflammation. Pharmacologic autophagy inhibition (chloroquine, 3-MA) preserves BBB integrity and reduces mortality, whereas autophagy induction (rapamycin) exacerbates BBB disruption and lethality.
Impact: It identifies endothelial autophagy as an actionable pathway for preventing neurovascular injury in sepsis and cautions against indiscriminate autophagy induction in acute inflammation.
Clinical Implications: Autophagy modulation emerges as a potential strategy to preserve BBB integrity in septic encephalopathy; existing drugs (e.g., chloroquine derivatives) warrant careful, targeted evaluation regarding timing and dosing.
Key Findings
- Proteomics of CLP mouse brain microvessels shows enrichment of autophagy-lysosome pathways and increased endothelial autophagic flux peaking at 24 h.
- LPS increases autophagic flux in brain endothelial cells (bEnd.3) in a dose- and time-dependent manner.
- Autophagy inhibitors (chloroquine, 3-MA) prevent BBB disruption and reduce CLP-induced lethality, whereas rapamycin worsens both.
Methodological Strengths
- Multi-tier approach combining in vivo CLP/LPS models, quantitative proteomics, reporter assays, and pharmacologic modulation.
- Demonstration of both mechanistic causality and survival impact.
Limitations
- Specificity of pharmacologic autophagy modulators may involve off-target effects.
- Translation to human septic encephalopathy remains to be established.
Future Directions: Define optimal therapeutic windows for autophagy modulation, validate endothelial autophagy markers in patients with sepsis, and assess neurologic outcomes in translational models.
The blood-brain barrier (BBB) protects the brain but becomes compromised during systemic inflammatory conditions such as sepsis. The mechanisms driving BBB disruption remain incompletely understood. Here, we identified a significant enrichment of the macroautophagy/autophagy-lysosome-related pathway in the upregulated proteome using quantitative proteomics on brain microvessels from mice after cecal ligation and puncture (CLP) that induces polymicrobial sepsis. CLP progressively induced autophagic flux in brain endothelial cells, peaking at 24 h post-procedure before subsiding. Similarly, an mRFP-GFP-LC3 reporter assay and immunoblotting showed that lipopolysaccharide (LPS) treatment increased autophagic flux in bEnd.3 cells in a time- and dose-dependent manner. Mice intraperitoneally (IP) injected with the autophagy inhibitors chloroquine (CQ) or 3-methyladenine (3-MA) were resistant to BBB disruption caused by CLP or IP injection of LPS, whereas those injected with the autophagy inducer rapamycin (Rapa) were more susceptible. CQ and 3-MA reduced, while Rapa increased, CLP-induced lethality in mice. These effects were confirmed
3. Macrophage C3aR1 Mediates Sepsis-Induced Myocardial Injury by Triggering Neutrophil Necroptosis.
Complement receptor C3aR1 on macrophages drives M1 polarization via TLR4/NF-κB and triggers neutrophil necroptosis, forming a feed-forward inflammatory loop that culminates in septic cardiomyopathy. Cardiac-specific C3aR1 knockdown disrupts this loop, reducing myocardial injury and improving function in vivo.
Impact: It defines a concrete, druggable node (C3aR1) linking innate immune cell crosstalk to cardiac injury in sepsis, providing a mechanistic basis for complement-targeted interventions.
Clinical Implications: Complement pathway modulation—specifically C3aR1 blockade—may mitigate septic cardiomyopathy by interrupting macrophage–neutrophil inflammatory amplification, warranting translational development.
Key Findings
- C3aR1 promotes macrophage M1 polarization through the TLR4/NF-κB pathway in CLP-induced sepsis models.
- Activated M1 macrophages trigger neutrophil necroptosis, establishing a self-amplifying loop that drives cardiomyocyte injury and dysfunction.
- Cardiac-specific C3aR1 knockdown attenuates myocardial damage, reduces inflammatory infiltration, and improves cardiac function in vivo.
Methodological Strengths
- Convergent in vivo (CLP rat) and in vitro co-culture systems establish cell-cell causality.
- Genetic intervention (cardiac-specific C3aR1 knockdown) with functional outcomes strengthens translational relevance.
Limitations
- Species- and model-specific findings may not fully capture human septic cardiomyopathy.
- Therapeutic window, safety, and systemic effects of C3aR1 inhibition remain untested in large animals.
Future Directions: Develop selective C3aR1 inhibitors/biologics, define timing relative to sepsis phases, and validate macrophage–neutrophil necroptosis signatures in patients with septic cardiomyopathy.
Sepsis-induced myocardial injury (SIMI) is a leading cause of mortality in critically ill patients, driven by dysregulated immune-inflammation responses. Although macrophages and neutrophils are key players in this process, the mechanisms governing their crosstalk in SIMI remain unclear. Here, we demonstrate that the complement C3a receptor 1 (C3aR1) critically mediates this interaction. Using a cecal ligation and puncture (CLP)-induced SIMI rat model and an in vitro co-culture system with THP-1-derived macrophages, HL-60 cells and AC16 cardiomyocytes, we show that C3aR1 promotes macrophage M1 polarisation via the TLR4/NF-κB pathway. The activated M1 macrophages subsequently trigger neutrophil necroptosis, leading to the release of chemokines and establishing a self-amplifying inflammatory loop from M1 polarisation to neutrophil necroptosis and cardiomyocyte injury, ultimately resulting in cardiac dysfunction. Cardiac-specific knockdown of C3aR1 in vivo attenuated myocardial damage, reduced inflammatory cell infiltration and improved cardiac function. Our findings identify C3aR1 as a key molecular hub orchestrating macrophage-neutrophil crosstalk in SIMI and highlight its potential as a therapeutic target for mitigating sepsis-induced cardiac complications.